← Therapy pipeline
Investigational · Obesity development

CT-996

Roche

Oral small-molecule GLP-1 agonist in obesity Phase 2.

GLP-1
Other study areas
Type 2 diabetes
Selected program areas, not approvals. See the full profile for individual trials.
Obesity stagePhase 2Updated as of November 2026
SponsorRoche
TargetsGLP-1
RouteOral tablet
DevelopmentObesity-specific
01 / Evidence

Selected study results

Early oral obesity studyMean body-weight changeBody weight decreased 7.3% · 4 weeks · Phase 1
Phase 1 · Oral · Sponsor-reported numerical results

Mean body-weight change · 4 weeks

Study focus: Weight management without type 2 diabetes

CT-996
7.3%
Placebo
1.2%

Adults with obesity without type 2 diabetes · Oral CT-996; dose not specified in this topline summary · N not included in this summary · Sponsor-reported 4-week result. Results & methods ↗

Short early study; longer-duration Phase 2 outcomes are needed.

Each graphic shows results within one study. Alternate analyses and follow-up from that study are labeled together. Study averages are not individual predictions or cross-trial comparisons.

02 / How it works

Mechanism at a glance

GLP-1GLP-1Targeted
GIPGIP—
GCGglucagon—
AMYamylin—
OTHOther targets—
Explore the hormone anatomy ↗
03 / Development

Obesity stage by formulation

TabletOral tablet · Once daily
Phase 2Phase 2 obesity study completed; results pending
Milestone → next

Latest: The Phase 2 obesity study NCT07081958 is completed in the October 26, 2026 registry update; no registry results are posted.

Next: Phase 2 obesity efficacy and safety results.

04 / Study records

Clinical study records

Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.

Obesity and weight-management studies

Phase 2 studies1 record

Phase 2

CT-996 obesity program

Weight management
Study: CompletedResults: No registry results posted yetStatus reviewed November 2026

Longer-duration oral obesity evaluation.